CAS: 169939-93-9; (7S)-7-((Dimethylamino)Methyl)-22,25-Dihydro-11H,21H,31H-6-Oxa-1,3(3,1)-Diindola-2(3,4)-Pyrrolacyclononaphane-22,25-Dione Hydrochloride

主要参考文献

1: Pang C, Wen L, Lu X, Luo S, Qin H, Zhang X, Zhu B, Luo S. Ruboxistaurin maintains the bone mass of subchondral bone for blunting osteoarthritis progression by inhibition of osteoclastogenesis and bone resorption activity. Biomed Pharmacother. 2020 Sep 1;131:110650. doi: 10.1016/j.biopha.2020.110650. Epub ahead of print. 10(4):1960-1969. doi: 10.1021/acschemneuro.8b00259. Epub 2018 Nov 8.
3: Lewin AH, Brieaddy L, Deschamps JR, Imler GH, Mascarella SW, Reddy PA, Carroll FI. Synthesis and Characterization of the Selective, Reversible PKCβ Inhibitor (9 S)-9-[(Dimethylamino)methyl]-6,7,10,11-tetrahydro-9 H,18 H-5,21:12,17-dimethenodibenzo[ e,k]pyrrolo[3,4- h][1,4,13]oxadiazacyclohexadecine-18,20(19 H)-dione, Ruboxistaurin (LY333531). ACS Chem Neurosci. 2019 Jan 16;10(1):246-251. doi: 10.1021/acschemneuro.8b00196. Epub 2018 Sep 11. 2(6):669-683. doi: 10.1016/j.jacbts.2017.06.007.
5: Al-Onazi AS, Al-Rasheed NM, Attia HA, Al-Rasheed NM, Ahmed RM, Al-Amin MA, Poizat C. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. J Pharm Pharmacol. 2016 Feb;68(2):219-32. doi: 10.1111/jphp.12504. Epub 2016 Jan 28.

合成参考文献

参考文献:10.1038/s42255-020-00319-x
摘要:Martin-Perez M, Grillo AS, Ito TK, Valente AS, Han J, Entwisle SW, Huang HZ, Kim D, Yajima M, Kaeberlein M, Villén J. PKC downregulation upon rapamycin treatment attenuates mitochondrial disease. Nature Metabolism. 2020 Dec 14;2(12):1472–81. doi: 10.1038/s42255-020-00319-x.